The growth of Viagra and its influence on the drug landscape presents a complicated question for shareholders. While the first sales figures were impressive, the patent has expired, leading to a wave of copycat alternatives that are reducing earnings. Moreover, the sector is facing difficulties related to demographic trends and shifting healthcare